Published: May 28, 2021 By Gail Dutton
The U.S. cell and gene therapy market anticipates a wave of 10 to 20 approvals per year by 2025. To develop and commercialize them with maximum efficiency, the FDA, scientists and developers must innovate, according to panelists speaking during the Presidential Plenary on Commercialization at the
Addressing rare diseases is an important step as we move toward personalized medicine that “finds the right drug on the shelf,” and individualized medicine that “creates the right drug to treat the patient,” said Peter Marks, M.D., Ph.D., director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA). “It’s a paradigm. If we can get it right for the very small diseases, we can get it right for the larger indications.”
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.
Published: May 21, 2021 By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.
Thermo Fisher Scientific, UCSF to launch near-campus cell therapy manufacturing facility bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
NEW YORK, May 14, 2021 /PRNewswire/ PM360, the premier information resource for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device sectors, today announced the winners of